19 June 2013
Keywords: femara, effect, tamoxifen, new, data, suggest, novartis
Article | 07 January 2002
New data suggest that Novartis' aromatase inhibitor Femara (letrozole)may be more effective than the gold-standard therapy tamoxifen in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 January 2002
18 June 2013
© 2013 thepharmaletter.com